Authors: James Herron, Noel Smith, Laura Stanbery, Phylicia Aaron, Luisa Manning, Ernest Bognar, Gladice Wallraven, Staci Horvath, John Nemunaitis.
Recent research has focused on ways to activate and sustain an immune response. Vigil, an autologous tumor vaccine has shown both safety and efficacy in solid tumors. Here we show that advanced cancer patients exhibit reduced CD3+ T cells compared to healthy donor controls. Following vaccination with Vigil, the number of CD3+and CD3+CD8+ T cells increases to levels comparable to healthy controls. This data is suggestive that Vigil is able to generate a systemic cytotoxic T lymphocyte response.
View/Download pdf